Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Cisplatin
Related studies linked through entity extraction aliases.
Lobaplation or Cisplatin in Adjuvant Chemotherapy for Esophageal Carcinoma
- Status
- COMPLETED
- Phase
- PHASE4
Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Efficacy of Ulinastatin for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients
- Status
- COMPLETED
- Phase
- PHASE3
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck
- Status
- WITHDRAWN
- Phase
- PHASE3
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)
- Status
- COMPLETED
- Phase
- PHASE2
Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Phase II Trial of Cisplatin-Docetaxel Induction Plus Concurrent 3-D Conformal Radiotherapy and Weekly Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE2
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Timing of Surgery in Nonmetastatic Osteosarcoma of the Pelvis and Sacrum
- Status
- UNKNOWN
- Phase
- NA
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
- Status
- COMPLETED
- Phase
- PHASE3
Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE3